Sodium Thiosulfate Dosing for Calciphylaxis
For hemodialysis patients with calciphylaxis, administer intravenous sodium thiosulfate 25 grams three times weekly immediately following each dialysis session; for non-dialysis patients, use 12.5-25 grams intravenously 2-3 times weekly, with treatment duration typically ranging from 3-6 months based on clinical response.
Dosing Regimen by Patient Population
Hemodialysis Patients (Standard Approach)
The most commonly reported and effective regimen is:
- Dose: 25 grams IV
- Frequency: 3 times weekly (after each dialysis session)
- Duration: 3-6 months, though some patients require up to 2 years 1
Alternative dosing ranges from 12.5-25 grams per session, 2-3 times weekly 1. The 25-gram dose appears most frequently in successful case reports 2, 3, 4.
Key administration detail: Give sodium thiosulfate immediately following hemodialysis completion, not before or during, as the drug is substantially renally excreted and dialyzable 5.
Non-Dialysis/Peritoneal Dialysis Patients
For patients not on hemodialysis:
- Dose: 12.5-25 grams IV
- Frequency: 2-3 times weekly
- Duration: 3-6 months 1
Critical caveat: Sodium thiosulfate is substantially excreted by the kidneys, so the risk of toxic reactions is greater in patients with impaired renal function 5. These patients require closer monitoring for adverse effects, particularly metabolic acidosis.
Peritoneal Dialysis Alternative Route
Intraperitoneal administration has been reported:
Important warning: 80% of patients using intraperitoneal sodium thiosulfate experienced adverse effects requiring discontinuation, including chemical peritonitis 6. This route should be reserved for patients where IV access is problematic.
Treatment Duration and Monitoring
Duration considerations:
- Initial treatment: 3-6 months is standard 1
- Extended therapy: Some patients require up to 24 months for complete resolution 2, 8
- Continue until complete wound healing or maximum clinical improvement achieved
- One case demonstrated successful 34-month treatment without toxicity 4
Monitoring requirements:
- Blood pressure during each infusion (hypotension is common) 5
- Anion gap metabolic acidosis (occurs frequently, may require dosage adjustment) 4, 9
- Serum electrolytes and acid-base status
- Wound healing progress
Expected Outcomes and Response
Effectiveness:
- 44-80% achieve successful wound healing depending on administration route 6
- Pain relief typically occurs within weeks to months 2, 3
- Complete resolution may take 6-24 months 2, 8
Mortality considerations: Despite treatment, calciphylaxis carries 50-67% mortality, often from sepsis and infectious complications 6, 9. Early initiation of sodium thiosulfate is critical 3.
Common Adverse Effects and Management
Most frequent side effects 9:
- Metabolic acidosis (57% of patients) - may require dose reduction
- Nausea/vomiting (55% of patients) - usually manageable, rarely requires discontinuation
- Hypotension (less common) - monitor blood pressure during infusion 5
Dose adjustment: Required in approximately 9% of cases due to toxicity 9. If metabolic acidosis develops, consider reducing dose to 12.5 grams or decreasing frequency to twice weekly.
Critical Drug Interaction
Do not co-administer with hydroxocobalamin - sodium thiosulfate is chemically incompatible and must not be given through the same IV line 5.
Complementary Management
While sodium thiosulfate is the primary pharmacologic intervention, concurrent measures are essential:
- Discontinue vitamin K antagonists (warfarin increases calciphylaxis risk 11-fold) 1
- Stop vitamin D supplementation if present (72.7% of cases had this risk factor) 9
- Avoid calcium-based phosphate binders 1
- Aggressive wound care and debridement
- Optimize dialysis adequacy
Pharmacokinetic Considerations
The elimination half-life is approximately 182 minutes after high-dose IV administration in normal subjects, but is markedly prolonged (478 minutes) in anuric hemodialysis patients 5, 4. Approximately 20-50% is excreted unchanged by the kidneys 5. This prolonged half-life in dialysis patients supports the three-times-weekly dosing schedule aligned with dialysis sessions.